The role of suprapubic catheter insertion in preventing urinary tract infections following intravesical Botulinum toxin A

Intravesical botulinum toxin A (BTX-A) is recommended for the management of refractory detrusor overactivity [1]. Recognised side effects include increased urinary tract infections (UTIs) rates and voiding dysfunction, which may be related. Management of voiding dysfunction may require catheterisation [2]. While use of clean intermittent self-catheterisation (CISC) after BTX-A is well reported in the literature [2], we are not aware of any evidence detailing use of suprapubic catheter (SPC) concomitant or following intravesical BTX-A. We report a case series of women from our institution with concomitant BTX-A and SPC, who were unable or unwilling to consider CISC, and a control group of 4 who did not have a SPC, but had voiding difficulties.